The consensus remains at US$14.50 despite weaker earnings fo...

Moomoo AI Nov 12, 2023 20:46

The consensus remains at US$14.50 despite weaker earnings forecast, suggesting a belief in a minimal long-term impact to valuation. Yet, the rise in anticipated losses next year and reduced revenue predictions might raise investor concerns about Theravance Biopharma.

Bearish: Analysts Just Cut Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenue and EPS Estimates

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

4738 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4952

Followers

Following

11K

Visitors